Drug-Coated Balloon, Myocardial Infarction
Conditions
Keywords
Drug-Coated Balloon, De Novo, Restenotic Coronary Artery Lesion, major adverse cardiac event, target-lesion revascularization, Myocardial infraction
Brief summary
This is an investigator-initiated, prospective, single-centre, non-randomized, all-comers registry that evaluates the safety and efficacy of any Paclitaxel Drug-Coated Balloon (DCB) for the treatment of coronary de novo lesion, in-stent restenosis, and small vessel disease in patients with coronary artery disease in Hong Kong. The recruitment time frame of this study is 1 year from 1st January 2022 to 30th December 2022.
Detailed description
Procedural strategy, adjuvant medical therapy and antiplatelet regime were left to the discretion of individual operators and their routine clinical practice. In brief, lesion preparation with predilatation using an uncoated balloon with or without the use of adjunctive therapy such as atherectomy or intracoronary lithotripsy to achieve residual diameter stenosis of less than 30% will be required before the usage of the study device. If the lesion meets the inclusion criteria without any of the exclusion criteria, the DCB of appropriate diameter and length can be applied with a minimum inflation time of 30-60 seconds. More than 1 lesion can be treated using the study device in the same vessel. Bail-out stenting is allowed as per operators' discretion. Baseline demographic, clinical and angiographic characteristics of each patient will be recorded. Both 6 and 12 months clinical outcomes and procedural outcomes will be assessed. Patient will be reviewed by the treating physicians before discharge and at clinic as per local practice. The primary clinical endpoint is the 12 months major adverse cardiac event (MACE), defined as a composite of death, Myocardial infraction (Q-wave and non-Q wave), emergent coronary artery bypass graft surgery, or repeat clinically driven target-lesion revascularization (TLR) by percutaneous or surgical methods. The primary procedural outcomes are device success which defined as achieving less than 50% residual stenosis after the usage of only the study device, the lesion success defined as achieving less than 50% residual stenosis of target lesion using any percutaneous method, and procedural success, defined as lesion success and no in-hospital MACE during the index admission. Categorical variables will be reported as percentages and counts, and continuous variables will be reported as means ± standard deviations. Data analysis will be performed using STATA version 15 software (College Station, Texas, USA).
Interventions
DEVICEA Paclitaxel Drug-Coated Balloon
Size: 2.0mm-4.0mm x 15-30mm Coated drug: Prevail TM
Sponsors
Chinese University of Hong Kong
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subject age \>18. 2. Subject (or legal guardian) understands the trial requirements and treatment procedures and provides written informed consent prior to any trial-specific tests or treatment. 3. Indication for a percutaneous intervention in native epicardial arteries or bypass graft including patients with stable coronary artery disease and acute coronary syndromes (non- ST-elevated myocardial infarction and ST-elevation myocardial infarction). 4. Target lesion must have a stenosis of \>50% and \<100% angiographically. 5. Target lesion much have an angiographic reference vessel diameter of 2.0-4.0 mm. 6. Successful predilatation of the target lesions as defined by angiographic visual estimate of \<30% residual stenosis without major (defined as \>NHLBI grade B) flow-limiting dissection. 7. Target lesion must have a Thrombolysis in Myocardial Infarction flow \>2 before applying DCB.
Exclusion criteria
1. Known history of an allergic reaction or significant sensitivity to paclitaxel or other analogue or derivative. 2. Known history of an allergic reaction or significant sensitivity to urea or its analogue or derivative. 3. Pregnant or breastfeeding woman. 4. Currently participating in an investigational drug or another device study that has not completed the primary end point or that clinically interferes with the current study endpoints.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Major adverse cardiac event (MACE) | 12 month | Major adverse cardiac events (MACE) were defined as the composite of total death; myocardial infraction; stroke, hospitalization because of heart failure; and revascularization, including percutaneous coronary intervention, and coronary artery bypass graft |
| Device success | 12month | device success which defined as achieving less than 50% residual stenosis after the usage of only the study device |
| Lesion success | 12 month | the lesion success defined as achieving less than 50% residual stenosis of target lesion using any percutaneous method |
| Procedural success | 12 month | the procedural success defined as lesion success and no in-hospital MACE during the index admission |
Countries
Hong Kong
Contacts
Primary ContactDaniel Xu
Outcome results
None listed